Skip to main content
. 2016 Nov 25;8(2):2971–2983. doi: 10.18632/oncotarget.13579

Figure 6. Small molecule inhibitor (R)-9bMS sensitizes TNK2 and its substrate AKT kinase phosphorylation compromising TNBC proliferation.

Figure 6

A. TNBCs were treated with TNK2 inhibitor (5μM, 24 hours); lysates were immunoprecipitated with TNK2 antibodies, followed by immunoblotting with pTyr-antibodies. B. TNBC were treated with TNK2 inhibitor (5μM, 24 hours); lysates were immunoprecipitated with pY176-AKT antibodies, followed by immunoblotting with pan AKT-antibodies C. TNK2 inhibitor (R)-9bMS reduces TNBC growth. Cells were treated with (R)-9bMS for 96hr and the number of viable cells were counted by trypan blue exclusion assay. Data represented as mean ± SEM (n = 2, three replicates).